Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Great Neck, NY
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Mineola, NY
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Mineola, NY
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
New York, NY
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Stony Brook, NY
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Raleigh, NC
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Toledo, OH
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Portland, OR
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Erie, PA
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Orangeburg, SC
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Austin, TX
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Burlington, VT
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Fairfax, VA
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Richmond, VA
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
Clinical Research Facility
mi
from
Marshfield, WI
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated:  1/29/2016
mi
from
St. John's,
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.
Status: Enrolling
Updated: 1/29/2016
mi
from
St. John's,
Click here to add this to my saved trials
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Status: Enrolling
Updated:  2/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Status: Enrolling
Updated: 2/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Adherence With Iron Sprinkles Among High-Risk Infants
Adherence With Iron Sprinkles Among High-Risk Infants
Status: Enrolling
Updated:  2/2/2016
Whittier Street Health Center
mi
from
Boston, MA
Adherence With Iron Sprinkles Among High-Risk Infants
Adherence With Iron Sprinkles Among High-Risk Infants
Status: Enrolling
Updated: 2/2/2016
Whittier Street Health Center
mi
from
Boston, MA
Click here to add this to my saved trials
Adherence With Iron Sprinkles Among High-Risk Infants
Adherence With Iron Sprinkles Among High-Risk Infants
Status: Enrolling
Updated:  2/2/2016
Boston Medical Center Pediatric Primary Care Clinic
mi
from
Boston, MA
Adherence With Iron Sprinkles Among High-Risk Infants
Adherence With Iron Sprinkles Among High-Risk Infants
Status: Enrolling
Updated: 2/2/2016
Boston Medical Center Pediatric Primary Care Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment
Status: Enrolling
Updated:  2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment
Status: Enrolling
Updated: 2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP
Status: Enrolling
Updated:  2/3/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Efficacy and Safety of IL-11 in DDAVP Unresponsive
Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP
Status: Enrolling
Updated: 2/3/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Status: Enrolling
Updated:  2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Status: Enrolling
Updated: 2/3/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Exercise Capacity in Pediatric Sickle Cell Anemia
The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia
Status: Enrolling
Updated:  2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Exercise Capacity in Pediatric Sickle Cell Anemia
The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia
Status: Enrolling
Updated: 2/3/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
PMK Medical Group, Inc., dba Ventura County Hematology Oncology Specialists
mi
from
Oxnard, CA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Mayo Clinic Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Ocala Oncology Center
mi
from
Ocala, FL
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Willamette Valley Cancer and Research / USOR
mi
from
Eugene, OR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Willamette Valley Cancer and Research / USOR
mi
from
Eugene, OR
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Northwest Cancer Specialists, P.C.
mi
from
Tulatin, OR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Northwest Cancer Specialists, P.C.
mi
from
Tulatin, OR
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
St. Francis Hospital
mi
from
Greenville, SC
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology-Dallas, PA Presbyterian
mi
from
Dallas, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology-Dallas, PA Presbyterian
mi
from
Dallas, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
MD Anderson Cancer Center Leukemia Group
mi
from
Houston, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
MD Anderson Cancer Center Leukemia Group
mi
from
Houston, TX
Click here to add this to my saved trials
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated:  2/5/2016
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Status: Enrolling
Updated: 2/5/2016
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials